Myeloma Paper of the Day, July 31st, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: A CAR enhancer consisting of BCMA fused to a low-affinity interleukin increases activity and persistence of CAR T cells by selectively inducing IL-2 signaling and enhancing T cell activation, allowing use of lower cell doses.”
Source: Robert Orlowski/X
A CAR enhancer increases the activity and persistence of CAR T cells
Authors: Taha Rakhshandehroo, Shreya R. Mantri, Heydar Moravej, Benjamin B. V. Louis, Ali Salehi Farid, Leila Munaretto, Kathryn Regan, Radia M. M. Khan, Alexandra Wolff, Zoe Farkash, Min Cong, Adrien Kuhnast, Ali Nili, Uk-Jae Lee, Harris H. Allen, Lea Berland, Ester Simkova, Safak C. Uslu, Soheil Tavakolpour, Jennifer E. Rowley, Elisabeth Codet, Haneyeh Shahbazian, Jessika Baral, Jason Pyrdol, Caron A. Jacobson, Omar Nadeem, Hadi T. Nia, Kai W. Wucherpfennig, and Mohammad Rashidian
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
